ClinicalTrials.gg
CompletedNCT00926185Updated Aug 9, 2021Results posted

A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)

A Phase 2 interventional study of Lifitegrast and Placebo in Dry Eye, sponsored by Shire. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
7th of 22
230 · median 38
Started
2009
the only one that year
Phase 2
2 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
5 of 22
Shire

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 1st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry Eye
  • ophthalmic delivery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form and HIPAA document
  • Willing and able to comply with all study procedures
  • Be at least 18 years of age
  • Patient-reported history of dry eye in both eyes
  • Demonstrate a positive response when exposed to the Controlled Adverse Environment model
  • A negative urine pregnancy test if female of and must use adequate throughout the study period

Exclusion criteria

Exclusion Criteria:

  • Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
  • Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the study period
  • Any blood donation or significant loss of blood within 56 days of Visit 1
  • Any history of immunodeficiency disorder, positive , , C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
  • Use of any topical ophthalmic preparations (including tear substitutes) 72 hrs prior to screening assessments and through the entire study period
  • Any significant illness that could interfere with study parameters
  • History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.
  • Known history of alcohol and/or drug abuse
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
230 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo Ophthalmic Solution

    Drug: Placebo

  • Experimental
    0.1% Lifitegrast

    Lifitegrast

    Drug: Lifitegrast

  • Experimental
    1.0% Lifitegrast

    Lifitegrast

    Drug: Lifitegrast

  • Experimental
    5.0% Lifitegrast

    Lifitegrast

    Drug: Lifitegrast

Interventions

  • Ophthalmic Solution

    Also known as: SAR 1118

  • DrugPlacebo

    Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84

    Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

    Time frame: Day 84

Secondary outcomes

  1. Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84

    Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

    Time frame: Baseline (Day 0) and Day 84

07

Results

Posted Mar 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Started57575858
Completed54514848
Not completed361010

Outcome measures

PrimaryInferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84

Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

Time frame:
Day 84
Reported as:
Mean · units on a scale
Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 842.03 ± 0.8681.92 ± 0.7681.83 ± 0.6802.05 ± 0.715
Statistical analysis
  • Lifitegrast 0.1% vs Placebo · Dunnett's test · p = 0.9381 · Treatment effect: 0.06 · 95% CI -0.26 to 0.39Analysis of covariance model with treatment, baseline, and site.
  • Lifitegrast 1.0% vs Placebo · Dunnett's test · p = 0.3585 · Treatment effect: 0.20 · 95% CI -0.13 to 0.53Analysis of covariance model with treatment, baseline, and site.
  • Lifitegrast 5.0% vs Placebo · Dunnett's test · p = 0.1375 · Treatment effect: 0.27 · 95% CI -0.06 to 0.60Analysis of covariance model with treatment, baseline, and site.
SecondaryInferior Corneal Staining Score Change From Baseline (CFB) to Day 84

Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=occasional; 2=countable; 3=uncountable, but not confluent; 4=confluent) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

Time frame:
Baseline (Day 0) and Day 84
Reported as:
Mean · units on a scale
Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Pre-CAE: Baseline1.78 ± 0.4731.82 ± 0.5081.77 ± 0.5151.65 ± 0.513
Pre-CAE: CFB to Day 840.25 ± 0.8410.10 ± 0.7350.05 ± 0.7730.40 ± 0.802
Post-CAE: Baseline3.18 ± 0.4173.28 ± 0.6103.16 ± 0.5233.04 ± 0.602
Post-CAE: Day 842.86 ± 0.9622.88 ± 0.8602.90 ± 0.9182.62 ± 0.855

Adverse events

Collected over From the first dose of study drug until the end of follow-up visit, up to Day 86. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lifitegrast 0.1%—2/57 (3.5%)20/57 (35.1%)
Lifitegrast 1.0%—1/57 (1.8%)13/57 (22.8%)
Lifitegrast 5.0%—0/58 (0%)40/58 (69%)
Placebo—1/58 (1.7%)11/58 (19%)
Most frequent serious events
Most frequent serious events
EventLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Cardiac arrestCardiac disorders0/571/570/580/58
Hip fractureInjury, poisoning and procedural complications1/570/570/580/58
Oxygen saturation decreasedInvestigations1/570/570/580/58
AsthmaRespiratory, thoracic and mediastinal disorders0/570/570/581/58
Most frequent other events
Most frequent other events
EventLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Instillation site irritationGeneral disorders7/575/5720/586/58
Instillation site painGeneral disorders6/573/5720/583/58
Instillation site reactionGeneral disorders0/571/578/580/58
DysgeusiaNervous system disorders1/572/577/580/58
Visual acuity reducedEye disorders6/572/571/583/58
Conjunctival haemorrhageEye disorders0/572/573/580/58

Baseline characteristics

Intent-to-treat (ITT) set included all randomized participants.

Age, Continuous
Age, Continuous(years)Lifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%PlaceboTotal
Mean63.14 ± 13.10063.63 ± 11.88362.26 ± 12.22060.38 ± 12.93062.34 ± 12.523
Sex: Female, Male
Sex: Female, Male(Participants)Lifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%PlaceboTotal
Female47404745179
Male1017111351
08

Study locations

5 sites
  • The Eye Care Group
    Waterbury, Connecticut 06708, United States
  • Central Maine Eye Care
    Lewiston, Maine 04243, United States
  • Ora, Inc. (two locations)
    Andover, Massachusetts 01840, United States
  • Mundorf Eye Center
    Charlotte, North Carolina 28204, United States
  • Total Eye Care, P.A.
    Memphis, Tennessee 38119, United States
09

References and documents

Publications

  • Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, Kennedy KS, Ousler GW. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012 Jun;153(6):1050-60.e1. doi: 10.1016/j.ajo.2011.11.003. Epub 2012 Feb 11. PubMed 22330307 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Feb 2010, 6 months.

Results were first posted in Mar 2017, 7 years after primary completion. A results delay was requested in Jul 2013.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 6 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2009
First posted
Jun 23, 2009
StartActual
Aug 3, 2009
Primary completionActual
Feb 18, 2010
CompletionActual
Feb 18, 2010
Results delay requested
Jul 2, 2013
Results first posted
Mar 6, 2017
Last update
Aug 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00926185
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jun 23, 2009
Start date
Aug 3, 2009
Primary completion
Feb 18, 2010
Completion
Feb 18, 2010
Results posted
Mar 6, 2017
Last update
Aug 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifitegrast

Start the discussion